Kouvaraki Maria, Zerdes Ioannis, Sifakis Emmanouil G, Sarafidis Michail, Matikas Alexios, Tzoras Evangelos, Kjällquist Una, Stathopoulou Konstantina, Lövrot John, Alkodsi Amjad, Hartman Johan, Sotiriou Christos, Richard Francois, Hatschek Thomas, Herold Nikolas, Bergh Jonas, Rassidakis George Z, Foukakis Theodoros
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Breast Cancer Center, Karolinska University Hospital and Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
Int J Cancer. 2025 Apr 15;156(8):1621-1633. doi: 10.1002/ijc.35319. Epub 2024 Dec 27.
Sterile alpha motif and HD domain-containing protein 1 (SAMHD1) is a dNTP hydrolase important for intracellular dNTP homeostasis and serves as tumor suppressor and modulator of antimetabolite efficacy in cancer, though largely unexplored in breast cancer (BC). A cohort of patients with early BC (n = 564) with available gene expression data (GEP) was used. SAMHD1 protein expression was assessed by immunohistochemistry performed on tissue microarrays. A large pooled transcriptomic dataset was used for validation (n = 2402). GEP data from the metastatic TEX randomized phase III trial (NCT01433614) were used for SAMHD1 predictive evaluation in response to capecitabine. SAMHD1 protein and mRNA levels were higher in HER2-enriched/HER2+ and basal-like (BL)/ER-/HER2- BC. Both SAMHD1 gene and protein expression were independently associated with favorable outcomes in BL tumors. In the pooled dataset, SAMHD1 gene expression was independently associated with favorable disease-free survival in the entire population and within the BL and HER2-enriched molecular subtypes. In metastatic BC, SAMHD1 mRNA levels were higher in responders receiving capecitabine. In conclusion SAMHD1 gene and protein expression represent promising prognostic biomarkers in BL early BC.
含无菌α基序和HD结构域蛋白1(SAMHD1)是一种对细胞内脱氧核苷酸三磷酸(dNTP)稳态很重要的dNTP水解酶,在癌症中作为肿瘤抑制因子和抗代谢药物疗效的调节剂,不过在乳腺癌(BC)中其作用很大程度上尚未得到探索。我们使用了一组有可用基因表达数据(GEP)的早期BC患者(n = 564)。通过对组织微阵列进行免疫组织化学来评估SAMHD1蛋白表达。一个大型汇总转录组数据集用于验证(n = 2402)。来自转移性TEX随机III期试验(NCT01433614)的GEP数据用于评估SAMHD1对卡培他滨反应的预测价值。在HER2富集/HER2 +和基底样(BL)/雌激素受体(ER)阴性/HER2阴性BC中,SAMHD1蛋白和mRNA水平较高。SAMHD1基因和蛋白表达均与BL肿瘤的良好预后独立相关。在汇总数据集中,SAMHD1基因表达与整个人群以及BL和HER2富集分子亚型内的无病生存期良好独立相关。在转移性BC中,接受卡培他滨治疗的反应者中SAMHD1 mRNA水平较高。总之,SAMHD1基因和蛋白表达代表了BL早期BC中有前景的预后生物标志物。